4.6 Article

Kinetic and Structural Aspects of Glycosaminoglycan-Monkeypox Virus Protein A29 Interactions Using Surface Plasmon Resonance

Journal

MOLECULES
Volume 27, Issue 18, Pages -

Publisher

MDPI
DOI: 10.3390/molecules27185898

Keywords

A29; chondroitin sulfate; dermatan sulfate; heparin; monkeypox virus; surface plasmon resonance

Funding

  1. NIH [S10OD028523]
  2. GlycoMIP, a National Science Foundation Materials Innovation Platform [DMR-1933525]
  3. New York State Biodefense Commercialization Fund

Ask authors/readers for more resources

Monkeypox virus (MPXV) is spreading globally, with an increase in cases through intimate personal contact, particularly in the United States. This study shows that the MPXV A29 protein binds to GAGs, including heparin and chondroitin sulfate/dermatan sulfate, and the negative charges on GAGs are crucial for this interaction. GAG analogs, such as pentosan polysulfate and mucopolysaccharide polysulfate, can effectively inhibit the binding of MPXV A29 to heparin.
Monkeypox virus (MPXV), a member of the Orthopoxvirus genus, has begun to spread into many countries worldwide. While the prevalence of monkeypox in Central and Western Africa is well-known, the recent rise in the number of cases spread through intimate personal contact, particularly in the United States, poses a grave international threat. Previous studies have shown that cell-surface heparan sulfate (HS) is important for vaccinia virus (VACV) infection, particularly the binding of VACV A27, which appears to mediate the binding of virus to cellular HS. Some other glycosaminoglycans (GAGs) also bind to proteins on Orthopoxviruses. In this study, by using surface plasmon resonance, we demonstrated that MPXV A29 protein (a homolog of VACV A27) binds to GAGs including heparin and chondroitin sulfate/dermatan sulfate. The negative charges on GAGs are important for GAG-MPXV A29 interaction. GAG analogs, pentosan polysulfate and mucopolysaccharide polysulfate, show strong inhibition of MPXV A29-heparin interaction. A detailed understanding on the molecular interactions involved in this disease should accelerate the development of therapeutics and drugs for the treatment of MPXV.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available